Company intelligence / Profile preview

ADORIKA

Lyon, Auvergne-Rhône-Alpes, France

Ownership: Private
Development stage: Other

Overview

Adocia has developed a broad pipeline of specialty products for the treatment of type 1 and type 2 diabetes, as well as obesity. Its lead programs include innovative insulin formulations such as BC Lispro and BC Combo, both partnered in Asia. Clinical results have demonstrated improved glycemic control with these novel formulations. The company also has ongoing negotiations with Sanofi regarding M1Pram.

Therapeutic areas: Endocrinology
Modalities: Small moleculePeptidesProteinCell therapy
Industry: Biotech

Partnerships

Tonghua Dongbao (China/Asia licensing partner for insulins)Sanofi (exclusive negotiation rights on M1Pram)Eli Lilly (previous collaboration ended in regaining full rights by Adocia)

Beyond the preview

Go deeper on ADORIKA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADORIKA.

Explore the full profile